butylscopolammonium bromide has been researched along with physostigmine in 8 studies
| Studies (butylscopolammonium bromide) | Trials (butylscopolammonium bromide) | Recent Studies (post-2010) (butylscopolammonium bromide) | Studies (physostigmine) | Trials (physostigmine) | Recent Studies (post-2010) (physostigmine) |
|---|---|---|---|---|---|
| 695 | 165 | 149 | 6,230 | 252 | 331 |
| Protein | Taxonomy | butylscopolammonium bromide (IC50) | physostigmine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.1666 | |
| Acetylcholinesterase | Tetronarce californica (Pacific electric ray) | 0.3023 | |
| Cholinesterase | Homo sapiens (human) | 0.3055 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.2 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Acetylcholinesterase | Mus musculus (house mouse) | 0.0269 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.0853 | |
| Acetylcholinesterase | Bos taurus (cattle) | 0.7197 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 1.1821 | |
| Acetylcholinesterase | Gallus gallus (chicken) | 0.02 | |
| Acetylcholinesterase | Rattus norvegicus (Norway rat) | 0.0416 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.857 | |
| Cholinesterase | Equus caballus (horse) | 0.4081 | |
| Cholinesterase | Mus musculus (house mouse) | 0.28 | |
| Acyl-CoA:cholesterol acyltransferase | Oryctolagus cuniculus (rabbit) | 0.0189 | |
| Carboxylic ester hydrolase | Rattus norvegicus (Norway rat) | 0.018 | |
| Carboxylic ester hydrolase | Equus caballus (horse) | 1.263 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Fuchs, HF; Maeder, HU | 1 |
| Itoh, K; Kameyama, T; Nabeshima, T; Noda, Y | 1 |
| Betti, R; Casanueva, FF; Cella, SG; Mantegazza, P; Müller, EE | 1 |
| Bahar, M; Davidson, JT; Snir-Mor, I; Weinstock, M | 1 |
| Betti, R; Casanueva, F; Cocchi, D; Frigerio, C; Mantegazza, P; Müller, EE | 1 |
8 other study(ies) available for butylscopolammonium bromide and physostigmine
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
[Pharmacoradiography of the gastro intestinal tract (author's transl)].
Topics: Atropine; Butylscopolammonium Bromide; Gastrointestinal Diseases; Gastrointestinal Motility; Glucagon; Humans; Metoclopramide; Morphine; Oxyphenonium; Parasympatholytics; Physostigmine; Propantheline; Radiography | 1976 |
Role of cholinergic and GABAergic neuronal systems in cycloheximide-induced amnesia in mice.
Topics: Amnesia; Animals; Avoidance Learning; Baclofen; Bicuculline; Butylscopolammonium Bromide; Cycloheximide; Male; Mice; Muscimol; Physostigmine; Picrotoxin; Receptors, Cholinergic; Receptors, GABA-A; Scopolamine | 1988 |
Effect of agonists and antagonists of cholinergic neurotransmission on growth hormone release in the dog.
Topics: Animals; Blood-Brain Barrier; Butylscopolammonium Bromide; Dogs; Dose-Response Relationship, Drug; Female; Growth Hormone; Male; Mecamylamine; Nicotine; Oxotremorine; Physostigmine; Receptors, Cholinergic; Receptors, Muscarinic; Receptors, Nicotinic; Synaptic Transmission | 1983 |
Physostigmine antagonizes morphine-induced respiratory depression in human subjects.
Topics: Adolescent; Adult; Butylscopolammonium Bromide; Carbon Dioxide; Droperidol; Female; Humans; Male; Middle Aged; Morphine; Physostigmine; Preanesthetic Medication; Respiration; Tidal Volume | 1983 |
Growth hormone-releasing effect of an enkephalin analog in the dog: evidence for cholinergic mediation.
Topics: Acetylcholine; Animals; Atropine; Butylscopolammonium Bromide; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Dogs; Endorphins; Enkephalin, Methionine; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Hormones; Kinetics; Male; Naloxone; Physostigmine; Pimozide; Receptors, Muscarinic | 1980 |